OBJECTIVE: Mutations of ATP1A3 have been associated with rapid onset dystonia-parkinsonism and more recently with alternating hemiplegia of childhood. Here we report one child with catastrophic early life epilepsy and shortened survival, and another with epilepsy, episodic prolonged apnea, postnatal microcephaly, and severe developmental disability. Novel heterozygous mutations (p.Gly358Val and p.Ile363Asn) were identified in ATP1A3 in these children. METHODS: Subjects underwent next-generation sequencing under a research protocol. Clinical data were collected retrospectively. The biochemical effects of the mutations on ATP1A3 protein function were investigated. Postmortem neuropathologic specimens from control and affected subjects were studied. RESULTS: The mutations localized to the P domain of the Na,K-ATPase α3 protein, and resulted in significant reduction of Na,K-ATPase activity in vitro. We demonstrate in both control human brain tissue and that from the subject with the p.Gly358Val mutation that ATP1A3 immunofluorescence is prominently associated with interneurons in the cortex, which may provide some insight into the pathogenesis of the disease. SIGNIFICANCE: The findings indicate these mutations cause severe phenotypes of ATP1A3-related disorder spectrum that include catastrophic early life epilepsy, episodic apnea, and postnatal microcephaly. Wiley Periodicals, Inc.
OBJECTIVE: Mutations of ATP1A3 have been associated with rapid onset dystonia-parkinsonism and more recently with alternating hemiplegia of childhood. Here we report one child with catastrophic early life epilepsy and shortened survival, and another with epilepsy, episodic prolonged apnea, postnatal microcephaly, and severe developmental disability. Novel heterozygous mutations (p.Gly358Val and p.Ile363Asn) were identified in ATP1A3 in these children. METHODS: Subjects underwent next-generation sequencing under a research protocol. Clinical data were collected retrospectively. The biochemical effects of the mutations on ATP1A3 protein function were investigated. Postmortem neuropathologic specimens from control and affected subjects were studied. RESULTS: The mutations localized to the P domain of the Na,K-ATPase α3 protein, and resulted in significant reduction of Na,K-ATPase activity in vitro. We demonstrate in both control human brain tissue and that from the subject with the p.Gly358Val mutation that ATP1A3 immunofluorescence is prominently associated with interneurons in the cortex, which may provide some insight into the pathogenesis of the disease. SIGNIFICANCE: The findings indicate these mutations cause severe phenotypes of ATP1A3-related disorder spectrum that include catastrophic early life epilepsy, episodic apnea, and postnatal microcephaly. Wiley Periodicals, Inc.
Authors: Hendrik Rosewich; Andreas Ohlenbusch; Peter Huppke; Lars Schlotawa; Martina Baethmann; Inês Carrilho; Simona Fiori; Charles Marques Lourenço; Sarah Sawyer; Robert Steinfeld; Jutta Gärtner; Knut Brockmann Journal: Neurology Date: 2014-02-12 Impact factor: 9.910
Authors: Michelle K Demos; Clara Dm van Karnebeek; Colin Jd Ross; Shelin Adam; Yaoqing Shen; Shing Hei Zhan; Casper Shyr; Gabriella Horvath; Mohnish Suri; Alan Fryer; Steven Jm Jones; Jan M Friedman Journal: Orphanet J Rare Dis Date: 2014-01-28 Impact factor: 4.123
Authors: Adrian L Oblak; Matthew C Hagen; Kathleen J Sweadner; Ihtsham Haq; Christopher T Whitlow; Joseph A Maldjian; Francine Epperson; Jared F Cook; Mark Stacy; Jill R Murrell; Laurie J Ozelius; Allison Brashear; Bernardino Ghetti Journal: Acta Neuropathol Date: 2014-05-07 Impact factor: 17.088
Authors: Christian P Roenn; Melody Li; Vivien R Schack; Ian C Forster; Rikke Holm; Mads S Toustrup-Jensen; Jens P Andersen; Steven Petrou; Bente Vilsen Journal: J Biol Chem Date: 2018-11-08 Impact factor: 5.157
Authors: Irene J Chang; Margaret P Adam; Suman Jayadev; Thomas D Bird; Niranjana Natarajan; Ian A Glass Journal: Am J Med Genet A Date: 2017-11-01 Impact factor: 2.802